Genetic Biomarkers Associated With Child Language Development in Taiwan (II)

August 27, 2024 updated by: Chang Gung Memorial Hospital
A study of the relation between genetic biomarkers and child language development in Taiwan.

Study Overview

Status

Completed

Conditions

Detailed Description

The interaction between gene and environment (G×E) can be a very complicated process that influences child development. As a pilot study of child development biomarkers, this study investigates genes related to child language development and language disorder.

Study Type

Observational

Enrollment (Actual)

115

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taoyuan, Taiwan
        • Chang Gung Memoria Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Control and experimental groups

Description

Inclusion Criteria:

  • Age 2-18 y/o
  • Agree to sign informed consent

Exclusion Criteria of Healthy Child:

  • Central nervous system disease
  • Neuromuscular Disorders
  • Congenital Abnormality
  • Genetic Disease
  • Dysesthesia
  • Hearing Impairment

Inclusion Criteria of Child with language disorder:

  • Patients with Language Disorder
  • Age 2-18 y/o
  • Agree to sign informed consent

Exclusion Criteria of Child with language disorder:

  • Hearing Impairment
  • Inclusion Criteria of Adult:
  • His or her child participated in this study, and gene abnormality was found.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
control
healthy child
experimental
patients with language disorder
We use Whole-exome sequence (WES) to analyze if there is any gene mutations for DLD(developmental language disorder) children.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scores of cognitive function 1
Time Frame: baseline
Bayley Scales of Infant and Toddler Development (Scores from 0 to 140, higher scores mean a better outcome.)
baseline
Scores of cognitive function (2 y/o to 6 y/o)
Time Frame: baseline
Wechsler Preschool and Primary Scale of Intelligence (Scores from 0 to 200, higher scores mean a better outcome.)
baseline
Scores of cognitive function (6 y/o to 16 y/o)
Time Frame: baseline
Wechsler Intelligence Scale for Children (Scores from 0 to 200, higher scores mean a better outcome.)
baseline
Scores of cognitive function 3
Time Frame: baseline
Test of Nonverbal Intelligence-Fourth Edition (Scores from 0 to 60, higher scores mean a better outcome.)
baseline
Scores of language function 1
Time Frame: baseline
Peabody Picture Vocabulary Test-Revised (Scores from 0 to 124, higher scores mean a better outcome.)
baseline
Scores of language function 2
Time Frame: baseline
Preschool Language Impaired Scale(PLS)/Language Impaired Scale(LS) (PLS: Scores from 0 to 65, higher scores mean a better outcome. LS: Scores from 0 to 73, higher scores mean a better outcome.)
baseline
Gene test 1
Time Frame: baseline
Microarray (Use Axiom Genome-Wide TWB 2.0 Array Plate (TWB 2.0) to analyze SNPs of disease-related biomarkers.)
baseline
Gene test 2
Time Frame: baseline
Whole-Exome Sequencing (Use Burrows-Wheeler Aligner (BWA) 85, Samtools86, Picard, Genome Analysis Toolkit (GATK) to screen out the variant discovery and genotyping.)
baseline
Scores of general development
Time Frame: baseline

Comprehensive Developmental Inventory for Infants and Toddlers (Higher scores mean a better outcome.)

Applied for children aged 3-71 months. Assessing areas: Cognition, language, motor, social, and self-care skills. Every item is scored 0 or 1, indicating whether the child 'fails' or 'passess' that item.

baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scores of participation(2-5 y/o)
Time Frame: baseline
Assessment of Preschool Children's Participation (Scores from 0 to 45, higher scores mean a better outcome.)
baseline
Scores of participation(>6 y/o)
Time Frame: baseline
Children Assessment of Participation and Enjoyment and Preferences for Activity of Children (Higher scores mean a better outcome.)
baseline
Scores of activities
Time Frame: baseline
Functional Independence Measure for Children (Scores from 18 to 126, higher scores mean a better outcome.)
baseline
Scores of quality of life
Time Frame: baseline
Pediatric Quality of Life Inventory TM (Scores from 0 to 102, higher scores mean a better outcome.)
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Chia-Ling Chen, MD, PhD, Chang Gung Memorial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 2, 2021

Primary Completion (Actual)

July 31, 2022

Study Completion (Actual)

July 31, 2022

Study Registration Dates

First Submitted

August 19, 2022

First Submitted That Met QC Criteria

August 19, 2022

First Posted (Actual)

August 22, 2022

Study Record Updates

Last Update Posted (Actual)

August 28, 2024

Last Update Submitted That Met QC Criteria

August 27, 2024

Last Verified

August 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe